• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·DRAGARWQ.BO
Share

Dr. Agarwal's Eye Hospital Limited Stocks

₹ 5030.35Last Updated 21.07.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 251.32M

₹ 5030.35
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Dr. Agarwal's Eye Hospital Ltd. is a specialized medical facility offering a comprehensive range of ophthalmic services. Its extensive offerings span various specialties, encompassing cataract surgery, advanced corneal interventions (including LASIK and SMILE), retina treatment, orbit and oculoplasty, glaucoma management, uvea care, neuro-ophthalmology, pediatric ophthalmology, and strabismus correction, alongside optical dispensing. Beyond patient care, the hospital is committed to ongoing professional development through continuous training and actively participates in research and development initiatives. The company was established in 1957 by Jaiveer Agarwal, Tahira Agarwal, Amar Agarwal, and Athiya Agarwal, and maintains its primary operational base in Chennai, India.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

23.07.2026 19:58

Wall Street is expecting a strong earnings report from Intel. Why it might not stop the stock's decline

23.07.2026 19:43

Oil production in Kazakhstan has plummeted following the shutdown of the main terminal — Reuters

23.07.2026 19:20

IBM has lowered its revenue growth forecast. How is the company trying to reassure investors?

23.07.2026 19:02

Nasdaq has tightened its rules. Nearly 200 small companies are at risk of delisting.

23.07.2026 18:50

U.S. stocks plummeted at the opening bell: tech giants and oil prices dragged the indices down

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026